GlassScriptPhysician profile
Reba Suri
NPI 1154958767
$6,509.74
in general payments reported to CMS, 2019-2025
26 companies · $3,826 in 2025
The $3,826 reported for 2025 was more than what 88% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $309 · 2022: $466 · 2023: $422 · 2024: $1,487 · 2025: $3,826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,056 · Travel and Lodging: $1,606 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,056.19 |
| Travel and Lodging | $1,606.33 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,704.87 | 2022-2025 | Skyrizi, Rinvoq |
| Kerecis Limited | $1,265.49 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Arcutis Biotherapeutics, INC. | $458.26 | 2024-2025 | Zoryve |
| Amgen INC. | $421.46 | 2021-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $392.57 | 2024-2025 | Tremfya |
| Genzyme Corporation | $338.53 | 2021-2025 | |
| Pfizer INC. | $311.74 | 2023-2025 | |
| Lilly USA, LLC | $223.57 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Incyte Corporation | $174.38 | 2022-2025 | Opzelura |
| Biofrontera INC. | $166.81 | 2025 | |
| Ucb, INC. | $154.77 | 2025 | Bimzelx |
| Organon LLC | $148.85 | 2025 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $147.70 | 2023-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $93.05 | 2025 | |
| Convatec INC. | $92.46 | 2024-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $85.30 | 2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $82.16 | 2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.62 | 2025 | Spevigo |
| Botanix Sb INC | $42.36 | 2025 | Sofdra |
| Galderma Laboratories, L.P. | $36.69 | 2025 | Dysport, Aklief |
| Merz North America, INC. | $33.01 | 2025 | |
| Kyowa Kirin, INC. | $17.01 | 2024 | Poteligeo |
| Revance Therapeutics, INC. | $16.67 | 2025 | Daxxify |
| Journey Medical Corporation | $16.42 | 2025 | |
| Biowound Solutions, INC. | $15.18 | 2025 | Bio-Connekt |
| Almirall LLC | $14.81 | 2025 | Seysara |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reba Suri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.